UnitedHealth Joins Aetna, Humana in Exoskeleton Coverage for 16 Million
New Berkshire CEO Greg Abel’s Feb. 28 shareholder letter may outline plans for its $300 billion cash pile and address its recent UnitedHealth Group stake. Lifeward’s FDA-approved ReWalk exoskeleton gained Medicare Advantage coverage from Aetna, Humana and UnitedHealthcare, expanding access to about 16 million beneficiaries.
1. Abel’s Shareholder Letter May Address UNH Stake
Berkshire Hathaway’s first shareholder letter from CEO Greg Abel will be released on Feb. 28 alongside Q4 results. Investors expect commentary on the conglomerate’s $300 billion cash position and clarification on its recent UnitedHealth Group shareholding and future portfolio moves.
2. Lifeward Exoskeleton Gains Medicare Advantage Coverage
Lifeward’s FDA-approved ReWalk Personal Exoskeleton is now covered by Aetna, joining Humana and UnitedHealthcare, expanding Medicare Advantage access to roughly 16 million beneficiaries with spinal cord injuries. The move broadens market reach and could drive demand for the wearable robotics technology.